AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
156 hedge funds and large institutions have $462M invested in AMAG Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 52 increasing their positions, 51 reducing their positions, and 31 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
13% more capital invested
Capital invested by funds: $408M → $462M (+$53.9M)
2% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 51
8% less funds holding
Funds holding: 170 → 156 (-14)
36% less call options, than puts
Call options by funds: $5.66M | Put options by funds: $8.89M
45% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$14.6M |
| 2 |
Goldman Sachs
New York
|
+$9.32M |
| 3 |
Millennium Management
New York
|
+$7.43M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.63M |
| 5 |
AC
Armistice Capital
New York
|
+$2.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Robeco Institutional Asset Management
Rotterdam,
Netherlands
|
-$12.8M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$5.02M |
| 3 |
Two Sigma Investments
New York
|
-$4M |
| 4 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$3.12M |
| 5 |
RA
Royce & Associates
New York
|
-$2.77M |
AMAG Hedge Fund Activity: Q3 2019 in Review
156 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q3 2019, worth a combined $462M — up 13% from $408M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of AMAG and 17 opened new positions — a net loss of 14 holders — while 51 trimmed existing stakes and 52 added.
The largest buyer was Camber Capital Management, adding an estimated $14.6M. The largest seller was Robeco Institutional Asset Management, cutting an estimated $12.8M.
- 156 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q3 2019, down from 170 in Q2 2019.
- Funds reported $462M of AMAG Pharmaceuticals stock for Q3 2019, up 13% quarter-over-quarter.
- 17 funds opened new AMAG Pharmaceuticals positions in Q3 2019 and 31 closed out, a net change of -14 holders.
- The largest AMAG Pharmaceuticals buyer in Q3 2019 was Camber Capital Management, an estimated $14.6M added.
- The largest AMAG Pharmaceuticals seller in Q3 2019 was Robeco Institutional Asset Management, an estimated $12.8M sold.
Based on aggregated 13F filings for Q3 2019.